Pharmaceutical Leaders are set to meet at the anticipated NGP US Summit Next week to discuss reform
Once a powerful profit-machine, big pharma is stumbling ,the threat of further government intervention, drying product pipelines, fierce competition from generic manufacturers, consumer concerns about safety, and false marketing claims is forcing leaders to revisit operations to secure top line Growth. So leaders such as Judith Marquis, Group VP Genzyme, Jeffrey Nye, Chief Medical Officer J&J Pharmaceuticals and James Kirwin VP Global Clinical Operation Wyeth Pharmaceuticals are uniting with over 50 other figureheads at the renowned NGP US Summit next week in Florida to discuss future technology investments to strengthen the industry and improve efficiency to “weather the Healthcare Reform”.
Thomas Haverty – Global VP, Global Clinical Research, Schering-Plough is set to start proceedings and our sources tell us he will be talking about Responding to 21st Century Drug Development Challenge.
“While healthcare reform has dominated headlines, drug companies have come through the debate relatively untouched, but they need to invest wisely to strengthen under the inevitable changes,” Drew Contessa NGP US Summit Director.
The good news for the pharmaceutical industry is that it may emerge as a winner in the healthcare reform battle as new customers enter the system and price protections remain in force.
IMS Health, the drug industry forecasting firm, reports that the global pharmaceutical industry will grow 4% to 6% in 2010, up to $825 billion.
It is not very often that the industries elite meet like this and it is clear that significant changes will be outlined as a result.
For more information www.ngpsummit.com
No comments:
Post a Comment